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ABSTRACT
 Quinazoline and quinazolinone derivatives are well-known bioactive heterocycles owing to 
their therapeutic diversity and extensive medicinal application in drug design and pharmaceutics. 
A series of 2-methyl-3-substituted quinazolin-4(3H)-one derivatives 8a-q was herein synthesized 
from synthetic conversion of anthranilic acid to 2-methyl-4H-3,1-benzoxazi-4-one, 7 which was 
subsequently transformed to the targeted 2,3-disubstituted quinazolin-4(3H)-one derivatives 8a-q 
by reacting with some notable amino-containing moieties via an ameliorable pathway. The catalyst-
free synthesis was successful achieved by careful reaction optimization study using solvent choice 
and reaction temperature variability as key parameters. The chemical structures of the synthesized 
compounds were confirmed by IR, UV, 1H-NMR, 13C-NMR and DEPT-135 as well as analytical 
data. 
Keywords: Solvent-dependent synthesis, spectral study,
quinazolin-4(3H)-one, DEPT-135 analysis.
INTRODUCTION
 Heterocyclic compounds form the basis for 
pharmaceutical industry especially in the synthesis 
of drugs1. Also, most marketed drugs constitute of 
common structural units of heterocyclic compounds 
which could also be useful in the synthesis of 
biologically active agrochemicals2,3. For instance, 
in the pharmaceutical industry, among the top two 
hundred branded drugs, we have more than 75% 
of them which have heterocyclic fragments in their 
structures4. One of these organic compounds of 
interest among the heterocycles is quinazoline 
otherwise known as 1,3-diazanaphthalene, benzo-
1,3-diazine, benzopyrimidine which was first 
synthesized by Gabriel in 19035. Quinazoline 
can have different types of substituents attached 
to it, forming different derivatives of the parent 
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quinazoline. Substituted quinazolines have properties 
which largely depend on: the nature and position of 
the substituent as well as type of conjugation in 
pyrimidine ring6. quinazolinones alkaloids form 
small but important group of naturally occurring 
bases which have been isolated from a number 
of different families e.g. seeds of P. nigellastium 
Bunge7. Quinazoline occurs mostly as alkaloid in 
root and leaves of some medicinal plants such as 
Dichroa febrifuga (also called Chinese quinine) which 
belongs to the Saxifragaceae family8. Numerous 
quinazoline derivatives have also be synthesized in 
order to achieve biologically active template which 
are essential in drug development. For instance, 
quinazoline motifs have been reported to exhibit 
diverse biological and pharmacological activities 
which include anticonvulsant9, anti-inflammatory10, 
antileishmanial11, antimalarial12, antioxidant13, 
antitubercular14, antiviral15 among others. Vast amount 
of literature has been documented for the synthesis 
of quinazoline and quinazolinone on the catalyst 
supported synthesis of this crucial heterocyclic core, 
some of which are Ceryl ammonium nitrate (CAN) 
for synthesis of 116, Ru3(CO2)12 for 217, CuCl for 318, 
b-cyclodextrin/Montmorillonite for 419, iodine for 520 
and Fe/HCl for 621 (Fig. 1). Some of these catalysts 
are costly to get. Hence, we have herein embarked 
on the synthesis of our targeted quinazolinone 
derivatives in the catalyst-free medium by engaging 
reaction optimization study using variation of solvents 
and temperature parameters. 
  
EXPERIMENTAL
 All chemical compounds and reagents 
used were obtained from Sigma-Aldrich, USA except 
methanol and dichloromethane which were obtained 
from B.D.H. Chemicals, UK and were made available 
by Department of Chemistry, Covenant University. 
Solvents used were of analytical grade and were 
used directly without further purification. Melting 
points were determined in open capillary tubes using 
Stuart melting point apparatus and were uncorrected. 
The IR spectra were run in solid state using the Bruker 
FT-IR; while UV Spectrophotometric analyses of all 
the samples were run in ethanol, using UV-Genesys 
spectrophotometer in the Instrumentation Laboratory 
of Chemistry Department. The 1H-NMR and 13C-NMR 
of the compounds were run on Bruker NMR machine 
at 500 MHz AND 125 MHz respectively. Distortionless 
Enhancement Proton Transfer (DEPT-135) analysis 
was also investigated for effective characterization. 
The chemical shifts were measured with reference 
to tetramethylsilane (TMS) and the solvent used 
were CDCl3 and deuteriated DMSO depending on 
the solubility properties of the required compound. 
The elemental analysis (C, H, N) of the synthesized 
compounds were performed using a Flash EA 1112 
CHN elemental analyzer. Results were found to be 
in good agreement with the calculated values (Table 
3). All compounds were routinely checked by TLC 
on silica gel G plates and column chromatographic 
purifications were carried out on Merck silica gel F 
(Mesh 200-300). The progress of the reaction and 
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Fig. 1: Some quinazoline and quinazolinone compounds synthesized by catalytic support
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the level of purity of the compounds were routinely 
checked by TLC on silica gel plates using different 
solvent system based on the variation of polarity of 
the product of interest and the developed plates were 
visualized under UV light. All drying was conducted 
at reduced pressure with DHG-9023A Vacuum 
Oven.  
Synthesis of 2-methyl-4H-3,1-benzoxazin- 
4-one, 7
 Acetic anhydride (30 ml) was added to 
anthranilic acid (30 g, 220 mmol), under continuous 
stirring for 5 mins at room temperature. An exothermic 
reaction was observed, then the reaction mixture 
was cooled in a refrigerator for 5 mins, after which it 
was heated under reflux and the progress of reaction 
was monitored by TLC using dichloromethane (DCM) 
as the eluting solvent. The reaction was completed 
in 6 h. The reaction mixture was then cooled to 
room temperature, filtered by suction and washed 
with few portion of cold water. It was then air-dried 
to afford 2-methyl-4H-3,1-benzoxazin-4-one, 7 as 
white crystalline solid in excellent yield. 1H-NMR 
(500 MHz, CDCl3) dH: 7.96-7.94 (d, J = 9.68 Hz, 1H 
of Ar-H), 7.77-7.73 (t, J = 9.68 Hz, 1H, Ar-H), 7.46-
7.42 (t, J = 10.00 Hz, 1H, Ar-H), 7.42-7.40 (d, J = 
10.00 Hz, 1H of Ar-H), 2.59 (s, 3H, CH3). 13C-NMR 
(125 MHz, DMSO-d6) dC: 168.77, (C=O), 140.37, 
134.91, 130.74, 129.04, 127.82, 117.24, 114.52, 
20.92 ppm. DEPT 135 (125 MHz, CDCl3) dC: Positive 
signals are 129.11 (CH), 127.91 (CH), 117.14 
(CH), 114.04 (CH), 20.92 (CH3) ppm. No Negative 
signals. UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 214 
(4.108), 250 (4.936), 263 (4.423). IR (KBr, cm–1) n
max
: 
3020 (C-H aromatic), 2929 (C-H aliphatic), 2846 
(C-H aliphatic), 1743 (C=O of ester), 1620 (C=C), 
1576 (C=N), 1388s (CH3 deformation), 1109 (C-O 
of alkoxyl), 975s (=C-H), 826 (C=C, out-of-plane 
bending), 757 (Ar-H, bending and ring puckering).
General procedure for synthesis of 2-methyl-3-
substituted quinazolin-4(3H)-ones, 8a-q.
 2-Methyl-4H-3,1-benzoxazin-4-one, 7 (3.00 
g, 18.60 mmol) was dissolved in 10 ml of ethanol in 
a 250 ml round bottom flask and the reaction mixture 
was allowed to stir for 5 mins. at room temperature for 
complete dissolution, followed by the addition of the 
corresponding amino containing compounds (18.60 
mmol). The mixture was then heated under reflux for 
the required number of periods as determined by the 
TLC monitoring. The reaction mixture was allowed 
to cool, filtered by suction and air-dried to afford 
moderate to excellent yields of various 2-methyl-3-
substituted quinazolin-4(3H)-one derivatives, 8a-q.
Synthesis of 2,3-dimethylquinazolin-4(3H)-one, 
8a. 
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with methyl amine (0.62 
ml, 18.60 mmol) afforded 2,3-dimethylquinazolin-
4(3H)-one, 8a. 1H-NMR (500 MHz, CDCl3) dH: 
7.96-7.94 (d, J = 9.65 Hz, 1H of Ar-H), 7.77-7.73 (t, 
J = 9.00 Hz, 1H, Ar-H), 7.46-7.42 (t, J = 10.00 Hz, 
1H, Ar-H), 7.42-7.40 (d, J = 9.30 Hz, 1H of Ar-H), 
3.35 (s, 3H, CH3), 2.59 (s, 3H, CH3-C=N). 13C-NMR 
(125 MHz, DMSO-d6) dC: 168.77, (C=O), 140.37, 
134.91, 130.74, 129.04, 127.82, 117.24, 114.52, 
25.26, 20.92 ppm. DEPT 135 (125 MHz, CDCl3) 
dC: Positive signals are 129.11 (CH), 127.91 (CH), 
117.14 (CH), 114.04 (CH), 25.24 (CH3), 20.92 
(CH3) ppm. No Negative signals. UV-Vis.: lmax in nm 
(log e
max 
mol-1cm-1): 212 (4.192), 251 (4.897), 293 
(4.401). IR (KBr, cm–1) n
max
: 3020 (C-H aromatic), 
2929 (C-H aliphatic), 2845 (C-H aliphatic), 1691 
(C=O of amide), 1620 (C=C), 1576 (C=N), 1445m, 
1388s (CH3 deformation), 975s (=C-H), 826 (C=C, 
out-of-plane bending), 757 (Ar-H, bending and ring 
puckering).
Synthesis of 2-methyl-3-pentylquinazolin-4(3H)-
one, 8b
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with pentylamine 
(1.74 ml, 18.60 mmol) afforded 2-methyl-3-
pentylquinazolin-4(3H)-one, 8b. 1H-NMR (500 
MHz, CDCl3) dH: 7.71-7.63 (dd, J1 = 10.30 Hz, J2 
= 12.30 Hz, 2H, Ar-H), 7.28-7.26 (d, J = 12.3 Hz, 
2H, Ar-H), 4.74-4.73 (m, 1H, CH), 3.72-3.69 (d, J = 
10.20 Hz, 1H), 3.23-3.17 (t, J = 12.65 Hz, 1H), 2.41 
(s, 3H, CH3-C=N), 2.18-2.15 (d, J = 12.65 Hz, 1H), 
1.67-1.59 (m, 4H, 2 × CH2), 1.38-1.31 (t, J = 13.16 
Hz, 3H, CH3-CH2). 13C-NMR (125 MHz, DMSO-d6) 
dC: 171.39 (C=O), 153.92, 145.83, 133.65, 127.42, 
126.75, 126.25, 118.88, 40.98, 30.51, 27.38, 24.49 
(CH3), 22.58, 14.51 (CH3) ppm. DEPT 135 (125 MHz, 
CDCl3) dC: Positive signals are 133.65 (CH), 127.42 
(CH), 126.75 (CH), 126.25 (CH), 24.49 (CH3), 14.51 
(CH3). Negative signals are 40.98, 30.51, 27.38, 
22.58 ppm. UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 
251 (4.915), 251 (4.979), 293 (4.440). IR (KBr, cm–1) 
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n
max
: 3038 (C-H aromatic), 2935 (C-H aliphatic), 2851 
(C-H aliphatic), 1688 (C=O of amide), 1615 (C=C), 
1576 (C=N), 1436m (CH2 deformation), 1388s (CH3 
deformation), 977s (=C-H), 821(C=C, out-of-plane 
bending), 754 (Ar-H, bending and ring puckering), 
658.
Synthesis of 3-hexadecyl-2-methylquinazolin-
4(3H)-one, 8c
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with hexadecylamine 
(4.98 g, 18.60 mmol) afforded 3-hexadecyl-2-
methylquinazolin-4(3H)-one, 8c. 1H-NMR (500 MHz, 
CDCl3) dH: 8.64-8.62 (d, J = 7.10 Hz, 1H of Ar-H), 
7.95-7.94 (d, J = 7.60 Hz, 1H of Ar-H), 7.39-7.38 (t, 
J = 6.65 Hz, 1H of Ar-H), 6.99-6.96 (t, J = 6.95 Hz, 
1H of Ar-H), 2.11 (s, 3H, CH3-C=N), 1.56-1.54 (t, J 
= 6.80 Hz, 2H, N-CH2-CH2), 1.22-1.11 (m, 28H, 2 × 
CH2), 0.86-0.83 (t, J = 6.80 Hz, 3H, CH3-CH2). 13C-
NMR (125 MHz, DMSO-d6) dC: 174.38 (C=O), 168.33, 
141.04, 132.45, 130.78, 121.80, 119.90, 39.69 (CH2), 
31.65 (CH2), 29.52 (7 × CH2), 29.28 (CH2), 28.84 
(CH2), 28.25 (CH2), 27.93 (CH2), 26.47 (CH2), 25.33 
(CH3), 24.98 (CH2), 22.60 (CH2), 14.02 (CH3). DEPT 
135 (125 MHz, CDCl3) dC: Positive signals are 132.65 
(CH), 130.98 (CH), 121.95 (CH), 119.96 (CH), 25.39 
(CH3), 14.09 (CH3). Negative signals are 39.74 
(CH2), 31.65 (CH2), 29.52 (7 × CH2), 29.28 (CH2), 
28.84 (CH2), 28.25 (CH2), 27.93 (CH2), 26.47 (CH2), 
24.98 (CH2), 22.60 (CH2). UV-Vis.: lmax in nm (log emax 
mol-1cm-1): 209 (4.915), 248 (4.629), 299(3.833). IR 
(KBr, cm–1) n
max
: 3433 (O-H), 3142 (C-H aromatic), 
2918 (CH aliphatic), 2851 (CH aliphatic), 1690 (C=O 
of amide), 1660 (C=C), 1588 (C=N), 1437m (CH2 
deformation), 1375s (CH3 deformation), 970s (=C-H), 
825 (C=C, out-of-plane bending), 753 (Ar-H, bending 
and ring puckering).
Synthesis of (Z)-2-methyl-3-(octadec-9-en-1-yl)
quinazolin-4(3H)-one, 8d
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with oleylamine (4.48 
g, 18.60 mmol) afforded (Z)-2-methyl-3-(octadec-9-
en-1-yl)quinazolin-4(3H)-one, 8d. 1H-NMR (500 MHz, 
CDCl3) dH: 8.13-8.12 (d, J = 5.05 Hz, 1H of Ar-H), 
7.87-7.85 (t, J = 9.42 Hz, 1H, Ar-H), 7.46-7.42 (t, J 
= 10.00 Hz, 1H, Ar-H), 7.42-7.41 (d, J = 5.12 Hz, 
1H of Ar-H), 5.42-5.40 (t, J = 12.80 Hz, 2H, CH2-
CH=CH-CH2), 4.12 (t, J = 8.20 Hz, 2H, CH2-CH2), 
2.58 (s, 3H, CH3-C=N), 2.18-2.15 (m, 4H, 2 × CH2), 
1.67 (m, 2H, CH2), 1.31-1.29 (2H, CH2-CH2-CH3), 
1.29-1.25 (m, 20H, 10 × CH2), 0.95 (t, J = 8.54 Hz, 
3H, CH3-CH2). 13C-NMR (125 MHz, DMSO-d6) dC: 
171.21 (C=O), 154.61, 146.92, 133.54, 130.73 (2 × 
CH
 
olefin), 127.42, 126.84, 126.62, 120.92, 40.53 
(CH2), 31.80 (CH2), 30.91 (CH2), 29.90 (2 × CH2), 
29.71 (4 × CH2), 29.33 (2 × CH2), 27.84 (2 × CH2), 
26.70 (CH2), 22.90 (CH3), 22.61 (CH2), 14.33 (CH3) 
ppm. DEPT 135 (125 MHz, CDCl3) dC: Positive signals 
are 133.54 (CH), 130.73 (2 × CH
 
olefin), 127.42 (CH), 
126.84 (CH), 126.62 (CH), 22.90 (CH3), 14.33 (CH3) 
ppm. Negative signals are 40.53 (CH2), 31.80 (CH2), 
30.91 (CH2), 29.90 (2 × CH2), 29.71 (4 × CH2), 29.33 
(2 × CH2), 27.84 (2 × CH2), 26.70 (CH2), 22.61 (CH2) 
ppm. UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 215 
(5.434), 251(5.321), 293(4.762). IR (KBr, cm–1) n
max
: 
3038 (C-H aromatic), 3010 (C-H alkene), 2935 (C-H 
aliphatic), 2851 (C-H aliphatic), 1688 (C=O of amide), 
1615 (C=C), 1576 (C=N), 1436m (CH2 deformation), 
1388s (CH3 deformation), 977s (=C-H), 821 (C=C, 
out-of-plane bending), 754 (Ar-H, bending and ring 
puckering), 658.
Synthesis of 3-cyclohexyl-2-methylquinazolin-
4(3H)-one, 8e
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with cyclohexylamine 
(2.13 ml, 18.60 mmol) afforded 3-cyclohexyl-2-
methylquinazolin-4(3H)-one, 8e. 1H-NMR (500 MHz, 
CDCl3) dH: 8.03-8.01 (d, J = 5.09 Hz, 1H of Ar-H), 
7.86-7.82 (t, J = 9.45 Hz, 1H, Ar-H), 7.45-7.42 (t, J 
= 10.00 Hz, 1H, Ar-H), 7.38-7.41 (d, J = 5.12 Hz, 
1H of Ar-H), 3.54-3.51 (quintet, J = 4.50 Hz, 1H, 
CH2-CH-CH2), 2.59 (s, 3H, CH3-C=N), 1.77-1.63 (m, 
4H, 2 × CH2), 1.50-1.47 (quintet, J = 7.54 Hz, 2H, 
CH2-CH2-CH2), 1.21-1.13 (m, 4H, 2 × CH2). 13C-NMR 
(125 MHz, CDCl3) dC: 170.21 (C=O), 154.11, 146.12, 
133.25, 127.80, 126.91, 126.36, 120.54, 63.12, 31.42 
(2 × CH2), 25.80, 24.63 (2 × CH2), 22.98 (CH3) ppm. 
DEPT 135 (125 MHz, CDCl3) dC: Positive signals are 
133.25, 127.80, 126.91, 126.36 (CHs), 22.98 (CH3) 
ppm. Negative signals are 31.42 (2 × CH2), 25.80, 
24.63 (2 × CH2) ppm. UV-Vis.: lmax in nm (log emax 
mol-1cm-1): 215 (5.273), 251 (5.059), 296 (4.545). 
IR (KBr, cm–1) n
max
: 3040 (C-H aromatic), 2919 (CH 
aliphatic), 2845 (CH aliphatic), 1690 (C=O of amide), 
1620 (C=C), 1585 (C=N), 1435m (CH2 deformation), 
1370s (CH3 deformation), 970s (=C-H), 830 (C=C, 
out-of-plane bending), 755 (Ar-H, bending and ring 
puckering), 658.
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Synthesis of 2-methyl-3-phenylquinazolin-4(3H)-
one, 8f
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with aniline (1.70 ml, 
18.60 mmol) afforded 2-methyl-3-phenylquinazolin-
4(3H)-one, 8f. 1H-NMR (500 MHz, CDCl3) dH: 7.61-
7.59 (d, J = 10.00 Hz, 2H of Ar-H), 7.24-7.21 (m, 
5H, Ar-H), 7.10-7.08 (m, 2H, Ar-H), 2.40 (s, 3H, 
CH3-C=N). 13C-NMR (125 MHz, DMSO-d6) dC: 168.77 
(C=O), 139.75, 137.18, 132.91, 132.07, 129.33, 
129.15, 127.94, 125.64, 125.00, 123.40, 122.17, 
121.18, 118.64, 22.39 (CH3) ppm. DEPT 135 (125 
MHz, CDCl3) dC: Positive signals are 129.33 (CH), 
129.11 (CH), 125.50 (CH), 125.00 (CH), 123.40 
(CH), 122.17 (CH), 121.18 (CH), 118.64 (CH), 
22.35 (CH3) ppm. No negative signals. UV-Vis.: lmax 
in nm (log e
max 
mol-1cm-1): 218 (5.188), 302(4.403). 
IR (KBr, cm–1) n
max
: 3108 (C-H aromatic), 3041 (C-H 
aromatic), 2929 (CH aliphatic from CH3), 1690 (C=O 
of amide), 1610 (C=C), 1575 (C=N), 1450, 1375 (CH3 
deformation), 970s (=C-H), 831 (C=C, out-of-plane 
bending), 755 (Ar-H, bending and ring puckering), 
651.
S y n t h e s i s  o f  3 - ( 4 - c h l o r o p h e n y l ) - 2 -
methylquinazolin-4(3H)-one, 8g
Treatment of 2-methyl-4H-3,1-benzoxazin-4-one, 
7 (3.00 g, 18.60 mmol) with 4-chloroaniline (2.38 
g, 18.60 mmol) afforded 3-(4-chlorophenyl)-2-
methylquinazolin-4(3H)-one, 8g. 1H-NMR (500 MHz, 
CDCl3) dH: 8.68-8.67 (d, J = 5.40 Hz, 1H of Ar-H), 
8.09-8.08 (d, J = 10.09.  Hz, 1H, Ar-H), 7.77-7.60 
(m, 2H, ArH), 7.54-7.52 (d, J = 10.00 Hz, 2H, Ar-H), 
7.32-7.29 (d, J = 10.50 Hz, 1H, Ar-H), 7.09-7.08 
(d, J = 5.00 Hz, 1H, Ar-H), 2.23 (s, 3H, CH3-C=N). 
13C-NMR (125 MHz, DMSO-d6) dC: 168.77, (C=O), 
140.37, 134.91, 130.74, 129.04, 127.82, 117.24, 
114.52, 25.26, 20.92 ppm. DEPT 135 (125 MHz, 
CDCl3) dC: Positive signals are 129.11 (CH), 127.91 
(CH), 117.14 (CH), 114.04 (CH), 25.24 (CH3), 20.92 
(CH3) ppm. No negative signals. UV-Vis.: lmax in nm 
(log e
max 
mol-1cm-1): 218 (5.369), 245 (5.287), 299 
(4.690). IR (KBr, cm–1) n
max
: 3477, 3378 (N-H, two 
bands), 3191 (C-H aromatic), 3113 (C-H aromatic), 
2925 (CH aliphatic from CH3), 1693 (C=O of amide), 
1650, 1606 (C=C), 1582 (C=N), 1452, 1377 (CH3 
deformation), 968s (=C-H), 833 (C=C, out-of-plane 
bending), 805 (C-Cl stretching), 756 (Ar-H, bending 
and ring puckering), 655.
S y n t h e s i s  o f  3 - ( 4 - b r o m o p h e n y l ) - 2 -
methylquinazolin-4(3H)-one, 8h
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with 4-bromoaniline 
(3.20 g, 18.60 mmol) afforded 3-(4-bromophenyl)-
2-methylquinazolin-4(3H)-one, 8h. 1H-NMR (500 
MHz, DMSO-d6) dH: 1H-NMR (500 MHz, CDCl3) dH: 
8.18-8.14 (d, J = 5.80 Hz, 1H of Ar-H), 8.02-7.98 
(d, J = 7.86 Hz, 1H, Ar-H), 7.74-7.58 (m, 2H, ArH), 
7.53-7.51 (d, J = 10.00 Hz, 2H, Ar-H), 7.28-7.25 (d, 
J = 10.54 Hz, 1H, Ar-H), 7.03-7.01 (d, J = 5.00 Hz, 
1H, Ar-H), 2.25 (s, 3H, CH3-C=N). 13C-NMR (125 
MHz, DMSO-d6) dC: 168.75 (C=O), 140.22, 137.40, 
134.82, 131.15, 131.01, 130.32, 129.00, 128.13, 
127.71, 125.31, 122.14, 117.04, 114.11, 25.12 ppm. 
DEPT 135 (125 MHz, CDCl3) dC: Positive signals are 
131.15, 131.01, 130.32, 129.00, 128.13, 127.71, 
117.04, 114.11 (CHs), 25.12 (CH3) ppm. No negative 
signals. UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 245 
(5.405), 206 (5.392), 296 (4.719). IR (KBr, cm–1) n
max
: 
3188 (C-H aromatic), 3110 (C-H aromatic), 2925 
(CH aliphatic from CH3), 1688 (C=O of amide), 1600 
(C=C), 1582 (C=N), 1449, 1373 (CH3 deformation), 
968s (=C-H), 835 (C=C, out-of-plane bending), 755 
(Ar-H, bending and ring puckering), 650, 505 (C-Br 
stretching).
S y n t h e s i s  o f  3 - ( 2 - a m i n o p h e n y l ) - 2 -
methylquinazolin-4(3H)-one, 8i
 Treatment of 2-methyl-4H-3,1-benzoxazin-4-
one, 7 (3.00 g, 18.60 mmol) with o-phenylenediamine 
(2.02 g, 18.60 mmol) afforded 3-(2-aminophenyl)-2-
methylquinazolin-4(3H)-one, 8i. 1H-NMR (500 MHz, 
DMSO-d6) dH: 1H-NMR (500 MHz, CDCl3) dH: 8.10-
8.07 (d, J = 5.70 Hz, 1H of Ar-H), 7.88-7.85 (d, J = 
7.80 Hz, 1H, Ar-H), 7.72-7.66 (m, 2H, ArH), 7.44-
7.40 (d, J = 10.05 Hz, 1H, Ar-H), 7.28-7.25 (d, J = 
10.54 Hz, 1H, Ar-H), 7.11-7.07 (m, 1H, Ar-H), 6.42 
(s, 2H, NH2), 2.35 (s, 3H, CH3-C=N). 13C-NMR (125 
MHz, DMSO-d6) dC: 171.05 (C=O), 154.60, 140.22, 
137.33, 134.81, 131.00, 130.32, 129.00, 128.13, 
127.71, 125.31, 122.14, 117.04, 114.11, 25.20 ppm. 
DEPT 135 (125 MHz, CDCl3) dC: Positive signals are 
131.00, 130.32, 129.00, 128.13, 127.71, 125.31, 
117,04, 114.11 (CHs), 25.20 (CH3) ppm. No negative 
signals. UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 206 
(4.997), 248 (4.598), 290 (4.223). IR (KBr, cm–1) 
n
max
: 3411 (N-H), 3255 (N-H), 3015 (C-H aromatic), 
2929 (C-H aliphatic), 2854 (C-H aliphatic), 1949, 
1685 (C=O of amide), 1615 (C=C aromatic), 1575 
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(C=N), 1450, 1385 (CH3 deformation), 1245 (C-N), 
968s (=C-H), 869 (C=C, out-of-plane bending), 760 
(Ar-H, bending and ring puckering), 650.
Synthesis of  3 ,3- (1 ,2-phenylene)bis(2-
methylquinazolin-4(3H)-one, 8j
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with o-phenylene 
diamine (1.01 g, 9.30 mmol, 0.5 equiv.) afforded 
3,3-(1,2-phenylene)bis(2-methyl quinazolin-4(3H)-
one, 8j. 13C-NMR (125 MHz, CDCl3) dC: 171.05 (2 
× C=O), 144.12 (2 × C), 140.91 (2 × C), 134.21 (2 
× C), 133.88 (2 × C), 127.31 (2 × C), 126.71 (2 × 
C), 126.60 (2 × C), 123.18 (2 × C), 120.77 (2 × C), 
114.33 (2 × C), 25.12 (2 × CH3). DEPT 135 (125 
MHz, CDCl3) dC: Positive signals are 127.31 (2 × CH), 
126.71 (2 × CH), 126.60 (2 × CH), 123.18 (2 × CH), 
120.77 (2 × CH), 114.33 (2 × CH), 25.12 (2 × CH3) 
ppm. No negative signals. UV-Vis.: l
max 
in nm (log 
e
max 
mol-1cm-1): 206 (4.909), 251(4.568), 296(4.130).
IR (KBr, cm–1) n
max
: 3050 (C-H aromatic), 3011 (C-H 
aromatic), 2925 (C-H aliphatic), 2857 (C-H aliphatic), 
1688 (C=O of amide), 1620 (C=C aromatic), 1576 
(C=N), 1451, 1386 (CH3 deformation), 1247 (C-N), 
969s (=C-H), 879 (C=C, out-of-plane bending), 760 
(Ar-H, bending and ring puckering), 655.
Synthes is  o f  3 - (2 -mercaptophenyl ) -2 -
methylquinazolin-4(3H)-one, 8k
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with 2-aminothiophenol 
(2.00 ml, 18.60 mmol) afforded 3-(2-mercaptophenyl)-
2-methylquinazolin-4(3H)-one, 8k. 1H-NMR (500 
MHz, CDCl3) dH: 8.11-8.07 (d, J = 5.68 Hz, 1H of 
Ar-H), 7.89-7.87 (d, J = 7.80 Hz, 1H, Ar-H), 7.70-
7.65 (m, 2H, ArH), 7.46-7.43 (d, J = 10.00 Hz, 1H, 
Ar-H), 7.7-7.22 (d, J = 10.50 Hz, 1H, Ar-H), 7.10-7.05 
(m, 1H, Ar-H), 3.42 (s, 1H, SH), 2.33 (s, 3H, CH3-
C=N). 13C-NMR (125 MHz, CDCl3) dC: 171.11 (C=O), 
144.38, 141.09, 137.13, 134.27, 131.09, 130.88, 
129.20, 128.11, 127.23, 125.73, 122.10, 117.04, 
114.11, 25.23 ppm. DEPT 135 (125 MHz, CDCl3) dC: 
Positive signals are 131.09, 130.88, 129.20, 128.11, 
127.23, 125.73, 118.23, 114.11 (CHs), 25.23 (CH3) 
ppm. No negative signals. UV-Vis.: l
max 
in nm (log 
e
max 
mol-1cm-1): 218 (5.310), 248 (4.969), 296 (4.497). 
IR (KBr, cm–1) n
max
: 3112 (C-H aromatic), 3029 (C-H 
aromatic), 2925 (CH aliphatic from CH3), 2556w (S-H 
of thiol, sharp & weak), 1690 (C=O of amide), 1610 
(C=C), 1585 (C=N), 1452, 1375 (CH3 deformation), 
970s (=C-H), 833 (C=C, out-of-plane bending), 756 
(Ar-H, bending and ring puckering), 651.
Synthesis of  3,3' - (1,4-phenylene)bis(2-
methylquinazolin-4(3H)-one), 8l
 Treatment of 2-methyl-4H-3,1-benzoxazin-4-
one, 7 (3.00 g, 18.60 mmol) with o-phenylenediamine 
(1.01 g, 9.30 mmol, 0.5 equiv.) afforded 3,3'-(1,4-
phenylene)bis(2-methyl quinazolin-4(3H)-one), 8l. 
1H-NMR (500 MHz, CDCl3) dH: 8.10-8.07 (d, J = 5.60 
Hz, 2H of 2 × Ar-H), 7.89-7.87 (d, J = 7.82 Hz, 2H, 2 
× Ar-H), 7.70-7.65 (m, 4H, 2 × Ar-H), 7.36-7.34 (d, J 
= 10.00 Hz, 4H, 2 × Ar-H), 2.26 (s, 6H, 2 × CH3). 13C-
NMR (125 MHz, CDCl3) dC: 170.23 (2 × C=O), 145.21 
(2 × C), 137.19 (2 × C), 134.02 (2 × C), 130.16 (2 × 
C), 129.38 (2 × C), 122.77 (2 × C), 117.09 (2 × C), 
25.22 (2 × CH3) ppm. DEPT 135 (125 MHz, CDCl3) 
dC: Positive signals are 137.19 (2 × CH), 134.02 (2 
× CH), 129.38 (2 × CH), 122.77 (2 × CH), 25.22 
(2 × CH3) ppm. No negative signals. UV-Vis.: lmax 
in nm (log e
max 
mol-1cm-1): 218(4.793), 251(4.545), 
305(3.851). IR (KBr, cm–1) n
max
: 3056 (C-H aromatic), 
3022 (C-H aromatic), 2925 (CH aliphatic from CH3), 
1688 (C=O of amide), 1600 (C=C), 1575 (C=N), 
1450, 1370 (CH3 deformation), 969s (=C-H), 831 
(C=C, out-of-plane bending), 755 (Ar-H, bending 
and ring puckering), 650.
Synthesis of 1-(2-methyl-4-oxoquinazolin-3(4H)-
yl)urea, 8m
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with semicarbazone 
(1.39 g, 18.60 mmol) afforded 1-(2-methyl-4-
oxoquinazolin-3(4H)-yl)urea, 8m.
1H-NMR (500 MHz, CDCl3) dH: 10.96 (s, 1H, NH), 
8.08-8.06 (d, J = 9.56 Hz, 2H, Ar-H), 7.81-7.68 (m, 
2H, Ar-H), 7.08 (s, 2H, NH2), 2.22 (s, 3H, CH3-C=N). 
13C-NMR (125 MHz, CDCl3) dC: 173.21 (C=O), 171.81 
(C=O), 151.18, 135.00, 132.27, 127.43, 117.04, 
116.82, 109.99, 25.23 (CH3) ppm. DEPT 135 (125 
MHz, CDCl3) dC: Positive signals are 135.00 (CH), 
132.27 (CH), 117.04 (CH), 116.82 (CH), 25.23 (CH3) 
ppm. No Negative signals. UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 221 (5.349), 302 (4.464), 545 (3.079). IR 
(KBr, cm–1) n
max
: 3415 (N-H), 3260 (N-H), 3176 (C-H 
aromatic), 2921 (C-H aliphatic), 2850 (C-H aliphatic), 
1949, 1688 (C=O of amide), 1606 (C=C aromatic), 
1584 (C=N), 1453, 1383 (CH3 deformation), 1248 
(C-N), 967s (=C-H), 879 (C=C, out-of-plane bending), 
766 (Ar-H, bending and ring puckering).
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Synthesis of 3-Amino-2-methylquinazolin-4(3H)-
one, 8n
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with hydrazine 
hydrate (0.91 ml, 18.60 mmol) afforded 3-amino-
2-methylquinazolin-4(3H)-one, 8n. 1H-NMR (500 
MHz, CDCl3) dH: 7.92-7.90 (d, J = 9.56 Hz, 2H, 
Ar-H), 7.30-7.27 (m, 2H, Ar-H), 6.50 (s, 2H, NH2), 
2.07 (s, 3H, CH3-C=N). 13C-NMR (125 MHz, CDCl3) 
dC: 173.21 (C=O), 151.18, 135.00, 132.27, 122.89, 
117.04, 116.82, 109.99, 20.78 (CH3) ppm. DEPT 
135 (125 MHz, CDCl3) dC: +ve signals are 135.00 
(CH), 132.27 (CH), 117.04 (CH), 116.82 (CH), 20.78 
(CH3) ppm. No –ve signals. UV-Vis.: lmax in nm (log 
e
max 
mol-1cm-1): 230 (5.443), 245(5.439), 320(5.089). 
IR (KBr, cm–1) n
max
: 3479 (N-H of NH2), 3394 (N-H), 
3185 (C-H aromatic), 3049 (C-H aromatic), 2921 
(C-H aliphatic), 1948 (C=C asym. stretching), 1689 
(C=O), 1652 (C=C), 1581 (C=N), 1453, 1376 (CH3 
deformation), 1245 (C-N), 968s (=C-H), 880 (C=C, 
out-of-plane bending), 756 (Ar-H, bending and ring 
puckering), 660.
Synthesis of 3-(2,4-dinitrophenylamino)-2-
methylquinazolin-4(3H)-one, 8o
 Tr e a t m e n t  o f  2 - m e t hy l - 4 H - 3 , 1 -
benzoxazin-4-one, 7 (3.00 g, 18.60 mmol) with 
2,4-dinitrophenylhydrazine (2,4-DNP) (3.59 g, 
18.30 mmol) afforded 3-(2,4-dinitrophenylamino)-2-
methylquinazolin-4(3H)-one, 8o. 1H-NMR (500 MHz, 
CDCl3) dH: 9.01 (s, 1H, Ar-H), 8.52-8.50 (d, J = 8.00 
Hz, 2H, Ar-H), 8.04-8.01 (d, J = 9.22 Hz, 1H, Ar-H), 
7.45-7.40 (d, J = 9.22 Hz, 1H, Ar-H), 7.38-7.36 (d, J 
= 8.00 Hz, 2H, Ar-H), 7.11.7.15 (m, 2H, Ar-H), 5.60 
(s, 1H, NH), 2.55 (s, 3H, CH3). 13C-NMR (125 MHz, 
CDCl3) dC: 171.21 (C=O), 151.18, 146.33, 140.12, 
135.15, 138.19, 132.03, 129.70, 126.73, 122.89, 
120.13, 117.84, 116.29, 109.99, 24.78 (CH3) ppm. 
DEPT 135 (125 MHz, CDCl3) dC: Positive signals are 
146.33, 140.12, 138.19, 135.15, 132.03, 117.84, 
116.29 (CHs), 24.78 (CH3) ppm. No negative signals. 
UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 218 (4.650), 
248(4.354), 347(4.130). IR (KBr, cm–1) n
max
: 3420 
(N-H), 3365 (N-H), 3100 (C-H aromatic), 3045 
(C-H aromatic), 2925 (C-H aliphatic), 2850 (C-H 
aliphatic), 1945 (C=C asym. stretching), 1690 (C=O), 
1622 (C=C), 1585 (C=N), 1535 (N-O Asymmetric 
stretching of NO2), 1455, 1376 (CH3 deformation), 
1315 (N-O symmetric stretching of NO2),1245 (C-N), 
970s (=C-H), 881 (C=C, out-of-plane bending), 755 
(Ar-H, bending and ring puckering), 665.
Synthesis of 2-Methyl-3-(naphthalen-2-yl)
quinazolin-4(3H)-one, 8p
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with á-naphthylamine 
(2.67 g, 18.60 mmol) afforded 2-methyl-3-
(naphthalen-2-yl)quinazolin-4(3H)-one, 8p. 1H-NMR 
(500 MHz, CDCl3) dH: 8.07-8.05 (d, J = 5.88 Hz, 1H, 
Ar-H), 8.03-8.01 (d, J = 5.68 Hz, 1H, Ar-H), 7.69-7.67 
(d, J = 8.00 Hz, 1H, Ar-H), 7.55-7.52 (m, 3H, Ar-H), 
7.47-7.43 (m, 2H, Ar-H), 7.28-7.26 (d, J = 10.29 Hz, 
1H, Ar-H), 2.41 (s, 3H, CH3-C=N). 13C-NMR (125 
MHz, DMSO-d6) dC: 168.74 (C=O), 144.21, 139.70, 
137.43, 132.61, 132.01, 129.36, 129.14, 127.89, 
126.82, 126.12, 125.57, 125.02, 124.71, 123.40, 
122.17, 121.18, 118.64, 22.40 (CH3) ppm. DEPT 135 
(125 MHz, CDCl3) dC: Positive signals are 139.70, 
132.61, 129.36 (CH), 129.14 (CH), 126.81, 126.12, 
125.57 (CH), 125.02 (CH), 123.40 (CH), 121.18 
(CH), 118.64 (CH), 22.40 (CH3) ppm. No negative 
signals. UV-Vis.: l
max 
in nm (log e
max 
mol-1cm-1): 224 
(5.349), 242 (5.444), 305 (4.971).IR (KBr, cm–1) 
n
max
: 2919 (C-H aliphatic), 2084, 1690 (C=O), 1610 
(C=C aromatic), 1485, 1369 (CH3 deformation), 
1246 (C-N), 960s (=C-H), 829 (C=C, out-of-plane 
bending), 758 (Ar-H, bending and ring puckering), 
654.
Synthesis of 2-Methyl-3-(3-(trimethoxysilyl)
propyl)quinazolin-4(3H)-one, 8q
 Treatment of 2-methyl-4H-3,1-benzoxazin-
4-one, 7 (3.00 g, 18.60 mmol) with 3-amino 
propyltrimethoxysilane (3.25 ml, 18.60 mmol) 
afforded   2-methyl-3-(3-(trimethoxysilyl) propyl)
quinazolin-4(3H)-one, 8q. 1H-NMR (500 MHz, CDCl3) 
dH: 7.94-7.92 (d, J = 9.56 Hz, 1H, Ar-H), 7.37-7.35 
(d, J = 8.00 Hz, 1H, Ar-H), 7.15-7.09 (m, 2H, Ar-H), 
4.14-4.11 (t, J = 5.44 Hz, 2H, N-CH2-CH2), 3.52 (s, 
9H, 3 × CH3, Si-O-CH3), 2.52 (s, 3H, CH3-C=N), 
1.68-1.65 (m, 2H, CH2), 1.22-1.25 (t, J = 7.56 Hz, 2H, 
Si-CH2-CH2). 13C-NMR (125 MHz, CDCl3) dC: 171.31 
(C=O), 135.20, 132.27, 127.45, 126.25, 122.89, 
117.04, 51.32 (3 × O-CH3), 46.27 (CH2), 23.48 
(CH2), 16.61 (S-CH2), 22.49 (CH3) ppm. DEPT 135 
(125 MHz, CDCl3) dC: Positive signals are 132.27, 
127.45, 126.25, 117.04 (CHs), 116.82 (CH), 51.32 (3 
× CH3), 22.49 (CH3) ppm. Negative signals are 46.27 
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(CH2), 23.48 (CH2), 16.61 (CH2) ppm. UV-Vis.: lmax 
in nm (log e
max 
mol-1cm-1): 215 (4.924), 248 (4.691), 
299(4.196). IR (KBr, cm–1) n
max
: 3101 (C-H aromatic), 
3022 (C-H aromatic), 2929 (C-H aliphatic), 2855 
(C-H aliphatic), 1945 (C=C asym. stretching), 1690 
(C=O), 1620 (C=C), 1575 (C=N), 1450, 1377 (CH3 
deformation), 1245 (C-N), 1050 (Si-OCH3, str. & brd.), 
973s (=C-H), 885 (C=C, out-of-plane bending), 755 
(Ar-H, bending and ring puckering), 668.
RESULT AND DISCUSSIONS
Chemistry
 Quinazolinone derivatives are important 
structural scaffolds found in various library of 
biologically active compounds which are medicinally 
useful agents in formulation, discovery of drugs 
and medicinal chemistry research. Hence, in 
the continuation of our effort on the synthesis of 
N-heterocyclic motifs1,2,4, we have herein achieved 
expeditious synthesis of 2-methyl-3-substituted 
quinazoline-4(3H)-one derivatives 8a-q, in a two 
steps technique. The first step of the synthesis in 
this present research work, involved the reaction 
of anthranilic acid with acetic anhydride according 
to a known procedure reported by Hassan et al22. 
in modified version to afford reactive intermediate 
2-methyl-4H-3,1-benzoxazin-4-one, 7 which was 
used as the reactive intermediate for the second step. 
The completion of the reaction was monitored with thin 
layer chromatography (TLC) using dichloromethane: 
methanol (9.5:0.5) as the eluting solvent system. The 
solid formed was filtered via suction and air-dried 
in order to afford 2-methyl-4H-3,1-benzoxazin-4-
one 7 in good yield (Scheme 1). However, before 
this intermediate was taking further to achieve all 
targeted compounds 8a-q, the reaction optimization 
study was carried out via the synthesis of 8a which 
was the first member of this series. Preliminary 
optimization of reaction conditions was done by 
considering the effect of solvent type and reaction 
temperature for the effective synthesis of 8a being the 
first and simplest 2-methyl-3-substitutedquinazolin-
4(3H)-one since the substituent at position-3 of its 
template was a methyl group. The synthesis of 8a 
was attempted in four different entries via thermal 
reaction of 2-methyl-4H-3,1-benzoxazine-4-one 
with methyl amine at reflux condition for 6 h using 
three solvents which were butanol, ethanol and 
dichloromethane as well as under solvent-free media 
(Table 1). This was done for comparative study of the 
efficiency of each solvent system for obtaining 8a. It 
was observed that the reaction in ethanol gave the 
most suitable condition for the synthesis of 8a, since 
it resulted in the highest yield (79.78%), followed by 
butanol (55.83%) and then dichloromethane which 
gave the lowest yield (45.35%). However, it was 
interesting to note that solvent-less medium resulted 
in no isolable product but reverted back to the staring 
material as indicated by the observation found in 
the TLC spotting which showed the presence of the 
starting material without any new spot for the product, 
while the solvent free medium gave the least yield 
(18.21%) as most of the starting material was not 
effectively converted to product as noticed in the TLC 
spotting monitoring. and therefore it was used in all 
subsequent experiments. The effect of temperature 
was studied by carrying out the synthesis of 8a 
at different temperatures; 40, 70, 100 and 130 oC 
(Table 2) using ethanol solvent which was unveiled 
as the best solvent during the solvent-dependent 
optimization study and the result was as shown in 
Table 2. At refluxing reaction temperature of 40 oC, 
the yield of 8a was 18.53% obtained; and as the 
temperature increased to 70 oC, the percentage 
yield of 8a also increased to 55.82%, while the 
highest yield of 8a was observed to be 79.78% 
at a reacting temperature of 100 oC. However, the 
percentage yield decreased sharply to 35.48% when 
the reaction was experimented at temperature of 
130 oC (Table 2). Hence, it was concluded that the 
optimum temperature for the expeditious synthesis 
Table 1: Investigation of solvent-dependent 
synthesis of (8a) under reflux condition 
Entry Solvent Time / h Yield / %
1 Ethanol  6 79.78
2 Butanol 6 55.83
3 Dichloromethane 6 45.35
4 Solvent free 6 NIPO
Table 2: Investigation of temperature-
dependent synthesis of (8a) in ethanol
Entry Solvent Temperature / oC Yield / %
1 Ethanol 130 35.48
2 Ethanol 100 79.78
3 Ethanol 70 55.62
4 Ethanol 40 18.53
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of 8a was 100 oC and in the presence of ethanol 
solvent. Therefore, the same reaction condition was 
subsequently use for the synthesis of the remaining 
sixteen 2-methyl-3-substituted quinazolin-4(3H)-one 
motifs, 8b-q through synthetic modification of the 
-COOC end by condensing it with various cheap 
and readily available amino containing compounds 
in the presence of ethanol at 100 oC (Scheme 2). 
The completion of the reaction was confirmed after 
6 h of refluxing using TLC spotting, then the solution 
was left to stand overnight in freezer chest for proper 
crystallization to afford the targeted 2-methyl-3-
substituted quinazolin-4(3H)-one derivative (8a-q) 
in appreciable yields.
Physico-chemical Analysis
 The result of the physico-chemical 
parameters of the synthesized compounds 8a-q 
was as shown in Table 3. These parameters 
investigated include molecular weight, Rf value, 
melting point, percentage yield, sample colour and 
elemental analytical result for carbon, hydrogen 
and nitrogen. The molecular weights of the targeted 
compounds ranged 174.08 for compound 8a to 
410.64 for compound 8d. The Rf value for the 
targeted compounds varied from 0.36 for compound 
8l to 0.91 for compound 8n. The Rf values did not 
only showed the level of purity for each compound 
but also established the polarity of these targeted 
compounds. The melting point of the targeted 
compounds 8a-q was also presented in Table 3. It 
showed that compound 8b and 8m had the highest 
melting point value of > 300 oC while compound 
8f has the lowest melting point value of 117-121 
oC. The melting points of other compounds, which 
include 8i, 8j, 8k and 8l, were not determined due 
to the fact that they were oily and liquid at room 
temperature. The inability of compound 8m to melt at 
the highest permissible limit (300 oC) of the melting 
point apparatus might be due to the presence of the 
Scheme 1: Synthesis of 2-methyl-4H-3,1-benzoxazin-4-one, 7.
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Scheme 2: Synthesis of the 2-methyl-3-substitutedquinazolin-4(3H)-one, 8a-q.
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additional side chain amide which had tendency to 
exhibit hydrogen bong formation. The next parameter 
is the percentage yield which varied from 49.90% for 
compound 8i to 99.54% for compound 8n. The colour 
of the synthesized compounds was determined via 
virtual observation to be seven different colours 
which are brown, cream, black, yellow, purple, 
red and white. Compounds 8a, 8b, 8d, 8e, 8g, 8h, 
8n and 8q were observed to be brown in colour, 
followed by compound 8c with cream colour while 
compounds 8f was black in colour. Compounds 
8i, 8j and 8k were observed to be yellow in colour 
followed by compounds 8l, 8q and 8q which were 
purple whereas, compound 8m was noticed to be 
white in colour. The result of the elemental analytical 
data for the carbon, hydrogen and nitrogen of the 
intermediate 7 and the targeted compounds 8a-q was 
the last parameter presented in Table 3. The result 
Table 3: Result of the physico-chemical parameters of synthesized compounds, 8a-q
Comp. Mol.  Rf Melting Yield  Sample   Elemental Analysis %
No. Formula  Value Pt. (oC) (%)  Colour      Calcd. (% Found)  
 (Mol. Wt.)     C H N
8a C10H10N2O  0.62a 285 79.78 Brown 68.95  5.79  9.18 
 (174.08)     (69.01) (5.73) (9.22) 
8b C14H18N2O  0.83a > 300 83.75 Brown 73.01  7.88  12.16 
 (230.31)     (72.97) (8.06) (12.11)
8c C25H40N2O  0.62a 278-281 98.10 Cream 78.07  10.48 7.28 
 (384.60)     (77.97)  (10.31) (7.14)
8d C27H42N2O  0.58a 267-272 85.65 Brown 78.97  10.31  6.82 
 (410.64)     (79.04) (10.28) (7.00)
8e C15H18N2O  0.89a 178-181 57.43 Brown 74.35  7.49  11.56 
 (242.32)     (74. 28) (7.54) (11.61)
8f C15H12N2O  0.71a 117-121 61.57 Black 76.25 5.12  11.86 
 (236.27)      (76.33) (4.97) (12.01)
8g C15H11N2OCl 0.72b 292-296 94.78 Brown 66.55  4.10  10.35 
  (270.71)     (66.41) (3.97) (10.42)
8h C15H11N2OBr  0.82 b 285-287 95.13 Brown 57.16  3.52  8.89
 (315.16)     (57.22) (3.66)  (9.02)
8i C15H13N3O  0.68a ND 49.90 Yellow 71.70 5.21  16.72 
 (251.28)      (71.55) (5.08) (16.61)
8j C24H18N4O2  0.66a ND 51.37 Yellow 73.08  4.60 14.20 
 (394.43)     (72.97)  (4.47) (14.32)
8k C15H12N2OS  0.60a ND 78.56 Yellow 67.14  4.51  10.44 
 (268.33)     (66.98) (4.39) (10.54)
8l C24H18N4O2  0.36a ND 60.47 Purple 73.08  4.60  14.20 
 (268.33)     (72.94) (4.51) (14.37)
8m C10H10N4O2  0.55a > 300 71.97 White 55.04 4.62  25.68 
 (218.21)      (54.97) (4.55) (25.75)
8n C9H9N3O  0.91a 138-140 99.54 Brown 61.70  5.18  23.99
 (175.19)     (61.88) (4.99)  (24.08)
8o C15H11N5O5  0.56 b 153-155 74.84 Red 52.79  3.25  20.52 
 (341.28)     (52.61) (3.31) (20.67)
8p C19H14N2O  0.72a 213-215 96.44 Purple 79.70  4.93  9.78 
 (286.33)     (79.62) (5.02) (9.87)
8q C19H14N2O  0.58a 258-261 81.52 Brown 55.88  6.88  8.69 
 (322.43)     (56.02) (7.04) (8.75)
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of elemental analysis did not only correlate well with 
the molecular masses of all synthesized compounds 
but also showed a consistent minimum difference of 
not more than ±0.39 between % calculated and % 
found for the carbon, hydrogen and nitrogen of the 
targeted products 8a-q. 
Spectroscopic Characterization
 The results of the electronic transition using 
uv spectroscopy was investigated in ethanol solution 
and the results is a presented in the experimental 
section showing the wavelength (l
max
) and the log of 
molar absorptivity (Log e
max
). The infrared analysis 
was carried out using Bruker Fourier-Transform 
Infrared (FT-IR) and the various absorption bands 
from stretching and bending vibrational frequencies 
were duly reported. The results of the infrared 
spectral data of all the synthesized compounds 
were as presented in the experimental section. 
The 1H-NMR and 13C-NMR as well as DEPT-135 
(Distortionless Enhancement by Polarization 
Transfer) of the reactive intermediate and targeted 
quinazolin-4-one motifs 8a-q were run in either 
DMSO-d6 or CDCl3 depending on the solubility 
behaviour of each of the compound to be analyzed 
per time.  The 1H-NMR spectrum of precursor 7 
was run in CDCl3. It showed the presence of four 
aromatic protons between d 7.96 and 7.40 ppm. 
They are 1H doublet at d 7.77-7.73 ppm which was 
in the neighborhood of 1H triplet since they both 
possessed the same coupling constant of 9.68 Hz. 
Similarly, the remaining two aromatic protons were 
observed as 1H doublet at d 7.46-7.42 ppm and 1H 
triplet at d 7.42-7.40 ppm with coupling constant of 
10.00 Hz. The 3H of methyl group was observed up-
field of TMS as a singlet at d 2.59 ppm. Apart from all 
other signals in 1H NMR of compound 7 which were 
replicated in representative targeted product 8a, it is 
crucial to note that the 1H NMR spectrum of 8a also 
showed one addition signal at chemical shift value of 
d 3.35 ppm. This authenticated the insertion of methyl 
group at the position 3 of compound 7 to afford 8a. 
It was worthy to note that these values fall within the 
range for aromatic protons (8.28-7.09 ppm) earlier 
reported by Ajani et al., (2010) who investigated the 
microwave assisted synthesis of a series of novel 
2-quinoxalinone-3-hydrazone23 which also belong to 
benzodiazine family like quinazolinone but with its 
own nitrogen heteroatom situated at position 1 and 
4 of the hetero ring system.
 The 13C-NMR spectrum of reactive 
intermediate 7 revealed the presence of nine carbon 
atoms which include a carbonyl at d168.77 ppm, one 
C=N carbon of imino at d 140.37 ppm six aromatic 
carbon at d134.91 ppm to 114.52 ppm, and the 
last carbon close to TMS was CH3 type at d 20.92 
ppm. Careful observation of the signals of 8a in 
comparison with that of compound 7 showed effective 
transformation of 2-methyl-4H-3,1-benzoxazin-4-
one, 7 to 2,3-dimethyl quinazolin-4(3H)-one, 8a by 
the virtue of one additional signal at d 20.92 ppm 
which was that of second methyl group found in 
8a but absent in 7. The most de-shielded signals 
in the 13C-NMR spectra in all of the compounds 
varied between d 173.3 and 172.8 ppm which were 
attributed to the presence of carbonyl of ester in 7 
and carbonyl of amide in 8a-q. It was in agreement 
with the earlier reported value by Al-Kawkabani et 
al. who investigated the synthesis of novel 2H,8H-
pyrano[2,3-f]chromene-2,8-dione based scaffolds 
under tandem knoevenagel condition24. 
 Furthermore, the infrared spectrum of the 
precursor 7 was run in KBr pellet and it showed 
the presence of C-H aromatic stretching vibrational 
frequency at 3020 cm-1 while that of C-H aliphatic 
was noticed as two bands at stretching vibrational 
frequencies of 2929 cm-1 and 2846 cm-1. The C=O 
of ester was responsible for the band at 1743 cm-1 
which was further confirmed by the presence of C-O 
of alkoxy group at 1109 cm-1. The absorption bands 
at n 1620 cm-1 and 1576 cm-1 depicted the presence 
of C=C aromatic and C=N imino functionalities 
respectively. The infrared spectroscopy spectrums 
of the synthesized compounds were run in KBr 
pellet using Bruker FT-IR machine.  According to 
the result of the 2-methylsubstituted quinazolinone 
(8a-q), the C-H band of the aromatic were found 
in the range 3188 cm-1 (8h) to 3011 cm-1 (8j); while 
the highest band for C-H of aliphatic was observed 
in 8b and 8d as 2935 cm-1 and the lowest was at 
2845 as seen in compounds 8a and 8e. The bands 
in the range of 1693 (8g) to 1685 (8i) depicted the 
presence of C=O of amide in compounds 8a to 8q. 
The C=C of compounds 8a-q absorbed at stretching 
vibrational frequency of 1660 cm-1 (8c) to 1600 cm-1 
(8l and 8h). The C=N imino functionality was present 
in all compound 8a-q at the stretching vibrational 
frequencies at region 1588 cm-1 (as found in 8c) to 
1575 cm-1 (which was common to compound 8f, 8l, 
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8g). It was worthy to note that deformed alkyl group 
was presence in compound 8a-q, by the virtue of 
CH3 group in position 2 of the quinazolinone ring 
and as a result of availability of CH2, CH, in some 
peculiar compounds. The vibrational frequencies 
for the CH3, CH2, CH, (deformation) was noticed at 
1485 cm-1 highest value of 1485 cm-1 for 8p while the 
lowest value for this was found at 1370 cm-1 for 8e. 
The absorption bands at 1248 cm-1 (8m) to 1245 cm-1 
(8o and 8n), depicted the presence of C-N functional 
moieties. Specifically speaking compound 8o alone 
showed an asymmetry stretching. The frequency 
herein reported for carbonyl of ester at 1743 cm-1 was 
further confirmed by comparing it with the findings 
of Lewis et al. who documented the various C=O 
stretching absorption vibration frequencies in infrared 
spectra25 ranged between 1685 cm-1 to 1758 cm-1. 
The C=N reported herein was within the ranged of 
the C=N of benzimidazole earlier reported in our 
previous study2. 
 The electronic absorption spectra featuring 
l
max
 (Log e
max
) of the synthesized compounds was run 
in ethanol because they were all soluble in ethanol 
and the result is as shown in the experimental section. 
The lowest wavelength in the electronic transition of 
the synthesized compounds in 8a-q was found at 
206 nm as seen in compounds 8i and 8j respectively. 
The lowest wavelength for the compounds were as 
a result of the p→p* transition of C=C which showed 
the presence of benzene ring in all the compounds. 
Other transitions found at longer wavelengths were 
bathochromic in nature and are due to presence of 
auxochromic group nitrogen atom which is able to 
delocalize its lone pair into the chromophoric group 
thereby extending the wavelength and affecting 
the intensity of the absorbance. The highest 
wavelength 545 nm (Log e
max
 = 3.08) was found in 
the uv electronic transition of the compound 8m. 
Specifically, the visible absorption spectrum of 8m, 
for instance, showed a low band at l
max 
= 221 nm (Log 
e
max
 = 5.35) which was the value for the confirmation 
of presence of phenyl ring while the bathochromic 
shift observed at l
max 
= 302 nm (Log e
max
 = 4.46) 
was due to the presence of an auxochrome imine 
(N=C). This was as a result o  p→n transition which 
may be ascribed to the auxochromic C=N group. The 
noticeable peaks seen at l
max 
= 545 nm (Log e
max
 = 
3.08) might be due to the p→n transition peculiar to 
the NH herein present in compound 2m, although, 
with low log of molar absorptivity. It is interesting 
to note that all the compounds have electronic 
transition which culminated into specific peaks in 
their uv spectra, including even the whitish coloured 
compounds. In addition, the uv-visible spectra of the 
quinazoline-4-one, 8a-8q experienced bathochromic 
shifts of about 15 - 30 nm to give higher max values 
at above 351 nm, which may be ascribed to the 
chromophoric C=N group; characteristic of K bands 
of C=N functional group26.
CONCLUSION
 As envisaged from reviewed literature and 
chemical behavioural pattern of 2-methyl-4H-3,1-
bnezoxazin-4-one, 7, the thermal annelation of this 
reactive intermediate with various amino-based 
compounds to afford the corresponding 2-methyl-
3-substitutedquinazolin-4(3H)-one derivatives, 8a-q 
was successful. The reaction optimization study 
revealed the crucial role of the careful choice of 
solvent and thermodynamic parameter in order 
to achieve the targeted compounds in good to 
excellent yields even in the absence of catalyst. The 
spectroscopic assignments for structural elucidation 
was in concordance with the proposed structures for 
the synthesized compounds. The titled compounds 
are good candidate for further study in term of the 
investigation of their antimicrobial and antimalarial 
potential for further drug development. 
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